- Home
- ATON vs ALLR Comparison
ATON vs ALLR Comparison
Compare ATON & ALLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATON
- ALLR
- Stock Information
- Founded
- ATON 1973
- ALLR 2004
- Country
- ATON British Virgin Islands
- ALLR United States
- Employees
- ATON N/A
- ALLR N/A
- Industry
- ATON Oil & Gas Production
- ALLR Biotechnology: Pharmaceutical Preparations
- Sector
- ATON Energy
- ALLR Health Care
- Exchange
- ATON Nasdaq
- ALLR Nasdaq
- Market Cap
- ATON 13.4M
- ALLR 15.8M
- IPO Year
- ATON N/A
- ALLR N/A
- Fundamental
- Price
- ATON N/A
- ALLR $1.63
- Analyst Decision
- ATON
- ALLR Strong Buy
- Analyst Count
- ATON 0
- ALLR 1
- Target Price
- ATON N/A
- ALLR $9.00
- AVG Volume (30 Days)
- ATON 86.9K
- ALLR 21.5M
- Earning Date
- ATON 09-26-2025
- ALLR 11-13-2025
- Dividend Yield
- ATON N/A
- ALLR N/A
- EPS Growth
- ATON N/A
- ALLR N/A
- EPS
- ATON N/A
- ALLR N/A
- Revenue
- ATON N/A
- ALLR N/A
- Revenue This Year
- ATON N/A
- ALLR N/A
- Revenue Next Year
- ATON N/A
- ALLR N/A
- P/E Ratio
- ATON N/A
- ALLR N/A
- Revenue Growth
- ATON N/A
- ALLR N/A
- 52 Week Low
- ATON $2.95
- ALLR $0.61
- 52 Week High
- ATON $23.01
- ALLR $3.71
- Technical
- Relative Strength Index (RSI)
- ATON N/A
- ALLR 57.64
- Support Level
- ATON N/A
- ALLR $1.78
- Resistance Level
- ATON N/A
- ALLR $1.92
- Average True Range (ATR)
- ATON 0.00
- ALLR 0.26
- MACD
- ATON 0.00
- ALLR 0.00
- Stochastic Oscillator
- ATON 0.00
- ALLR 27.42
About ALLR Allarity Therapeutics Inc.
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States.